Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR. 1998. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 178(4):1139–1144.

Sturchler D, Just M, Berger R, Reber-Liske R, Matile H, Etlinger H, Takacs B, Rudin C, Fernex M. 1992. Evaluation of 5.1 [NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults. Tropical and Geographical Medicine 44(1–2): 9–14.

Sturchler D, Berger R, Rudin C, Just M, Saul A, Rzepczyk C, Brown G, Anders R, Coppel R, Woodrow G, Pye D, Sorenson F, Gillessen D, Matile H, Reber-Liske R. 1995. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. American Journal of Tropical Medicine and Hygiene 53(4):423–431.

Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M. 1998. Evaluation of SPf66 malaria vaccine efficacy in Brazil. American Journal of Tropical Medicine and Hygiene 58(3):378–385.

Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Aponte JJ, Sarmiento LE, Lozada DM, Coronell CG, Ortega NM, Rosas JE, Alonso PL, Patarroyo ME. 1993. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia [comments]. Lancet 341(8847):705–710.

Valero MV, Amador R, Aponte JJ, Narvaez A, Galindo C, Silva Y, Rosas J, Guzman F, Patarroyo ME. 1996. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 14(15):1466–1470.

Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, Kester KE, Holland CA, Voss G, Cohen J, Stewart AV, Miller RS, Ballou WR, Heppner DG Jr. 2004. Safety and immunogenicity of RTS,S+TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys. American Journal of Tropical Medicine and Hygiene 70(5):499–509.

Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, Maier C, Andrews L, Andersen RF, Gilbert S, Poulton I, Webster D, Dubovsky F, Tierney E, Sarpotdar P, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Thornton GB, Hill AV. 2005. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23(7):857–864.

Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282(5388):476–480.

Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL. 2005. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infection and Immunity 73(5):2863–2872.

Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. 2005. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences USA 102(13):4836–4841



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement